Table 1.
Baseline characteristics
| Variable | TDM-guided cohort | Non-TDM-guided cohort | Total cohort |
|---|---|---|---|
| Patients, n | 95 | 27 | 122 |
| Sex, n (%) | |||
| Male | 34 (36) | 14 (52) | 48 (39) |
| Female | 61 (64) | 13 (48) | 74 (61) |
| Agea, median (IQR) | 59 (50–65) | 62 (54–69) | 59 (52–67) |
| Performance statusa, n (%) | |||
| 0 | 41 (43) | 13 (48) | 54 (44) |
| 1 | 45 (47) | 14 (52) | 59 (48) |
| ≥ 2 | 9 (10) | 0 (0) | 9 (7) |
| Subtype soft-tissue sarcoma, n (%) | |||
| Angiosarcoma | 6 (6) | 2 (7) | 8 (7) |
| Leiomyosarcoma | 33 (35) | 13 (48) | 46 (38) |
| Myxofibrosarcoma | 4 (4) | 2 (7) | 6 (5) |
| Sarcoma NOS | 11 (12) | 1 (4) | 12 (10) |
| Solitary fibrous tumor | 10 (11) | 1 (4) | 11 (9) |
| Synovial sarcoma | 9 (9) | 4 (15) | 13 (11) |
| Undifferentiated sarcoma | 5 (5) | 1 (4) | 6 (5) |
| Otherb | 17 (18) | 3 (11) | 20 (16) |
| Pazopanib starting dose, n (%) | |||
| 600 mg with food | 16 (17) | 0 (0) | 16 (13) |
| 800 mg fasted | 79 (83) | 27 (100) | 106 (87) |
| Previous lines of systemic treatment, n (%) | |||
| 0 | 13 (14) | 5 (19) | 18 (15) |
| 1 | 61 (64) | 15 (56) | 76 (62) |
| 2 | 13 (14) | 7 (26) | 20 (16) |
| ≥ 3 | 8 (8) | 0 | 8 (7) |
| Number of samples per patient, median (range) | 3 (1–10) | 3 (1–10) | 3 (1–10) |
| Pazopanib geometric mean (mg/L) per patient, median (IQR) | 30.6 (25.0–38.6) | 30.2 (24.4–35.1) | 30.5 (24.8–38.5) |
IQR interquartile range, NOS not otherwise specified, TDM therapeutic drug monitoring
aAt the start of pazopanib treatment
bSum of all patients with subtypes including < 5 patients. These include among others malignant peripheral nerve sheath tumor (n = 4), liposarcoma (n = 3), epithelioid hemangioendothelioma (n = 2), rhabdomyosarcoma (n = 2), and intima sarcoma (n = 2). Percentages may not add up to 100% due to rounding